Stockscreener 앱 받기
189.10
0.19%
0.3543
전일 마감가:
$188.75
열려 있는:
$189.23
하루 거래량:
597.65K
Relative Volume:
0.21
시가총액:
$40.20B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-26.74
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
+1.58%
1개월 성능:
+11.39%
6개월 성능:
+60.77%
1년 성능:
+408.09%
1일 변동 폭
$185.89
$190.50
1주일 범위
$179.39
$193.53
52주 변동 폭
$34.00
$193.82
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
189.11 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
479.19 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
665.58 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.78 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
274.89 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance UK
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid - simplywall.st
Revolution Medicines Inc. R (42Z.DU) Q4 FY2025 earnings call transcript - Yahoo Finance
Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th - GlobeNewswire Inc.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer - Zacks Investment Research
RVMD Maintains Rating by Wedbush -- Price Target Raised to $192.10 - GuruFocus
FDA panel confronting peptide controversy - STAT
symbol__ Stock Quote Price and Forecast - CNN
RVMD|Revolution Medicines Inc|Price:189.500|Chg%:+0.750 - TradingKey
Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review - GuruFocus
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA - Moomoo
Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA - TradingView
FDA accepts review of Revolution Medicines' dar... - Pluang
Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review - Stock Titan
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(RVMD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
RVMD Maintained by Needham -- Price Target Raised to $236 - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator - DirectorsTalk Interviews
Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook? - simplywall.st
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Anti-Cancer Upstart’s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position - NAI500
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS) - Seeking Alpha
Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum - Quiver Quantitative
All eyes on data on Biogen’s tau therapy - STAT
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor - simplywall.st
Truist reiterates Buy on Revolution stock, keeps $210 target By Investing.com - Investing.com India
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim - Moomoo
RVMD Maintained by Guggenheim -- Price Target Raised to $235 - GuruFocus
Revolution Medicines Is Maintained at Buy by Guggenheim - Moomoo
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich? - simplywall.st
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process - CancerNetwork
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach for patients - The Globe and Mail
Revolution Medicines (RVMD) Holds Steady Near Resistance—Consolidation or Catalyst Ahead?Vol Target Rebalance - dars.gov.et
EMA speeds up review of Revolution Medicines' d... - Pluang
Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion - Quiver Quantitative
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process - The Manila Times
Revolution Medicines, Inc. - Via Ritzau
EMA fast-tracks Revolution Medicines' pancreatic cancer drug review - Stock Titan
Revolution Medicines wins EU fast track review for cancer drug - Seeking Alpha
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
Pulling the plug on cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma - Stockhouse
There's a Revolution in Cancer. But Can Big Pharma Afford It? -- Heard on the Street -- WSJ - Moomoo
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com - Investing.com South Africa
RVMD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $195 - GuruFocus
Revolution Medicines stock hits all-time high at 193.12 USD - Investing.com
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Revolution Medicines Inc 주식 (RVMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
2.43%
0.49%
자본화:
|
볼륨(24시간):